Literature DB >> 2121409

In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans.

P Jynge1, T Skjetne, I Gribbestad, C H Kleinbloesem, H F Hoogkamer, O Antonsen, J Krane, O E Bakøy, K M Furuheim, O G Nilsen.   

Abstract

Magnetic resonance spectroscopy of fluorine (19F) has been used to noninvasively study the in vivo pharmacokinetics of a model drug, fleroxacin (a fluoroquinolone antibiotic agent), in healthy human subjects. After oral administration, fleroxacin was detected in 19F magnetic resonance spectra from both liver and calf muscle and four magnetic resonance examinations were undertaken during a 24-hour period. By combining plasma analysis by high performance liquid chromatography with the magnetic resonance data, the following pharmacokinetic parameters (mean values) were obtained: tmax, 1.4, 4.6, and 5.6 hours in liver, plasma, and muscle, respectively; Cmax, 53, about 250, and about 60 mumol/L in plasma, liver, and muscle, respectively; t1/2, 4.4 hours (fast phase) and 10.8 hours (slow phase) in liver and 14.2 hours in plasma. The study documents for the first time the potential use of 19F magnetic resonance spectroscopy to noninvasively observe the time-related changes of a fluorine-containing drug in human tissues after oral administration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121409     DOI: 10.1038/clpt.1990.183

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

Review 1.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.

Authors:  Markus Müller; Amparo dela Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

2.  Quantitative assessment of the hepatic pharmacokinetics of the antimicrobial sitafloxacin in humans using in vivoF magnetic resonance spectroscopy.

Authors:  Geoffrey S Payne; David J Collins; Peter Loynds; Graham Mould; Philip S Murphy; Andrzej S K Dzik-Jurasz; Preminda Kessar; Nazneen Haque; Masayuki Yamaguchi; Shogo Atarashi; Martin O Leach
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

Review 3.  Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future.

Authors:  Christian Joukhadar; Markus Müller
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 4.  Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution.

Authors:  Martin Brunner; Oliver Langer
Journal:  AAPS J       Date:  2006-04-14       Impact factor: 4.009

5.  Drug distribution. The forgotten relative in clinical pharmacokinetics.

Authors:  H G Eichler; M Müller
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

Review 6.  Fleroxacin clinical pharmacokinetics.

Authors:  A E Stuck; D K Kim; F J Frey
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

Review 7.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  In vivo NMR studies of neurodegenerative diseases in transgenic and rodent models.

Authors:  In-Young Choi; Sang-Pil Lee; David N Guilfoyle; Joseph A Helpern
Journal:  Neurochem Res       Date:  2003-07       Impact factor: 3.996

Review 9.  Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action.

Authors:  Alan J Fischman; Nathaniel M Alpert; Robert H Rubin
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

10.  Pharmacokinetics of [18F]fleroxacin in healthy human subjects studied by using positron emission tomography.

Authors:  A J Fischman; E Livni; J Babich; N M Alpert; Y Y Liu; E Thom; R Cleeland; B L Prosser; J A Correia; H W Strauss
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.